232 related articles for article (PubMed ID: 28659338)
1. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.
Zeng Z; Liu W; Tsao T; Qiu Y; Zhao Y; Samudio I; Sarbassov DD; Kornblau SM; Baggerly KA; Kantarjian HM; Konopleva M; Andreeff M
Haematologica; 2017 Sep; 102(9):1537-1548. PubMed ID: 28659338
[TBL] [Abstract][Full Text] [Related]
2. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
Dinner SN; Giles FJ; Altman JK
Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
4. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.
Piya S; Kornblau SM; Ruvolo VR; Mu H; Ruvolo PP; McQueen T; Davis RE; Hail N; Kantarjian H; Andreeff M; Borthakur G
Blood; 2016 Sep; 128(9):1260-9. PubMed ID: 27268264
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
6. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
7. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.
Carter BZ; Mak PY; Chen Y; Mak DH; Mu H; Jacamo R; Ruvolo V; Arold ST; Ladbury JE; Burks JK; Kornblau S; Andreeff M
Oncotarget; 2016 Apr; 7(15):20054-67. PubMed ID: 26956049
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
9. Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
Piya S; Andreeff M; Borthakur G
Autophagy; 2017 Jan; 13(1):214-215. PubMed ID: 27797294
[TBL] [Abstract][Full Text] [Related]
10. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.
Long X; Yu Y; Perlaky L; Man TK; Redell MS
Br J Haematol; 2015 Sep; 170(5):704-18. PubMed ID: 25974135
[TBL] [Abstract][Full Text] [Related]
11. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol regulates VEGFR-1 (FLT-1) expression and signaling in acute leukemia cells.
Casalou C; Costa A; Carvalho T; Gomes AL; Zhu Z; Wu Y; Dias S
Mol Cancer Res; 2011 Feb; 9(2):215-24. PubMed ID: 21209384
[TBL] [Abstract][Full Text] [Related]
13. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
14. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia: Therapy resistance and a potential role for tetraspanin membrane scaffolds.
Floren M; Gillette JM
Int J Biochem Cell Biol; 2021 Aug; 137():106029. PubMed ID: 34174403
[TBL] [Abstract][Full Text] [Related]
16. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.
Pei S; Minhajuddin M; D'Alessandro A; Nemkov T; Stevens BM; Adane B; Khan N; Hagen FK; Yadav VK; De S; Ashton JM; Hansen KC; Gutman JA; Pollyea DA; Crooks PA; Smith C; Jordan CT
J Biol Chem; 2016 Oct; 291(42):21984-22000. PubMed ID: 27573247
[TBL] [Abstract][Full Text] [Related]
17. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
18. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
19. A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia.
Williams MS; Amaral FM; Simeoni F; Somervaille TC
J Clin Invest; 2020 Mar; 130(3):1217-1232. PubMed ID: 31770110
[TBL] [Abstract][Full Text] [Related]
20. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
